276 related articles for article (PubMed ID: 26901106)
21. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
22. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
23. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
Longerich T
Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
[TBL] [Abstract][Full Text] [Related]
24. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway.
Wang SS; Chen YH; Chen N; Wang LJ; Chen DX; Weng HL; Dooley S; Ding HG
Cell Death Dis; 2017 Mar; 8(3):e2688. PubMed ID: 28333142
[TBL] [Abstract][Full Text] [Related]
25. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
26. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
Hua H; Zhu Y; Song YH
Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
[TBL] [Abstract][Full Text] [Related]
27. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
[TBL] [Abstract][Full Text] [Related]
28. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
29. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.
Li Y; Chen L; Chan TH; Liu M; Kong KL; Qiu JL; Li Y; Yuan YF; Guan XY
Gastroenterology; 2013 Jan; 144(1):179-191.e4. PubMed ID: 23022495
[TBL] [Abstract][Full Text] [Related]
30. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
[TBL] [Abstract][Full Text] [Related]
31. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade.
Datta J; Majumder S; Kutay H; Motiwala T; Frankel W; Costa R; Cha HC; MacDougald OA; Jacob ST; Ghoshal K
Cancer Res; 2007 Mar; 67(6):2736-46. PubMed ID: 17363595
[TBL] [Abstract][Full Text] [Related]
32. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
33. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
35. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
36. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
37. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
38. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.
Bi J; Liu Q; Sun Y; Hu X; He X; Xu C
J Recept Signal Transduct Res; 2021 Dec; 41(6):593-603. PubMed ID: 33108937
[TBL] [Abstract][Full Text] [Related]
39. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
Li SZ; Xu F; Sun CQ; Xu P
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
[TBL] [Abstract][Full Text] [Related]
40. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
